Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Sep 19;12(9):e231104.
doi: 10.1136/bcr-2019-231104.

Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis

Ross Leader  1   2 , Jake Cowen  3 , Surya Panicker Rajeev  1   4
Affiliations
Case Reports

Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis

Ross Leader et al. BMJ Case Rep. .

Corrected and republished in

Abstract

Sodium glucose co-transporter-2 inhibitors (SGLT2-i) have become a popular therapeutic strategy in the management of hyperglycaemia in type 2 diabetes mellitus. The primary site of action of SGLT2-i is at the proximal renal convoluted tubule. They work by blocking SGLT2 receptors, sodium-dependent glucose co-transport molecules, which in turn prevents glucose reabsorption, facilitating glucosuria, improving glycaemic control as well as a moderate degree of weight loss. We report the case of a 51-year-old woman admitted to the acute medical unit with abdominal pain and vomiting, who was diagnosed with euglycaemic diabetic ketoacidosis secondary to recent initiation of an SGLT2-i medication (dapagliflozin). Clinicians should be aware of this rare side effect of SGLT2-i, to circumvent delays in patient management.

Keywords: Diabetes; Drugs: Endocrine System; Unwanted Effects / Adverse Reactions.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. NICE. Algorithm for blood glucose lowering therapy in adults with type 2 diabetes. NICE guideline NG. 28.
    1. Zinman B, Wanner C, Lachin JM, et al. . EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373:2117–28. 10.1056/NEJMoa1504720 - DOI - PubMed
    1. Johns E, McKay G, Fisher M. SGLT2 inhibiors. Br J Cardiol 2017;24:68–71.
    1. Persson F, Nyström T, Jørgensen ME, et al. . Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab 2018;20:344–51. 10.1111/dom.13077 - DOI - PMC - PubMed
    1. Perkins BA, Cherney DZ, Partridge H, et al. . Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480–3. 10.2337/dc13-2338 - DOI - PubMed

Publication types

MeSH terms